Plain-English translation of NCT04289467 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , a medication, can help young children (ages 1 to 3 years old) whose infantile spasms — a serious type of seizure — haven't responded to the standard first-line treatments. Researchers want to see if this medication is safe and effective for these children, and whether it can reduce or stop their seizures.
Some children's seizures don't respond to the usual medications doctors try first. This trial exists to explore whether this medication could offer hope for families whose children have exhausted standard treatment options and still continue to have seizures.
You likely qualify if…
You likely don't qualify if…
Your child will have a baseline brain wave recording (video-EEG) to document their current seizure activity. Then your child will receive the medication for 21 days, with the dose gradually increased to a target level. After 21 days, your child will have another brain wave recording to see how the treatment is working. If your child responds well, you'll have the option to continue the medication for up to 6 months total.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States